Special Issue "Hippo Pathway in Cancer, towards Realization of the Hippo-Targeted Therapy"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (28 February 2018)
The Hippo pathway is the newest and possibly be the last addition to signalling pathways, which have ever been growing. We know now that the fundamental role of the pathway is the negative regulation of two transcription regulators, YAP1 and TAZ. YAP1/TAZ co-operate with TEAD and other transcription factors to regulate cell proliferation and differentiation.
Human cancers are frequently associated with deregulation of the Hippo pathway. The consequent hyperactivation of YAP1/TAZ and TEAD induces epithelial-mesenchymal transition and enhances drug resistance. Accordingly, the incidence of metastasis and recurrence is increased. It is reasonable to assume that inhibition of YAP1/TAZ and TEAD improves prognosis in cancer patients.
Hence, the development of drugs that target YAP1/TAZ and TEAD is one of the current topics in cancer therapy. Such reagents are indeed reported but are presumably the tip of the iceberg. We can imagine that the more promising candidates would be the more strictly kept in secrecy at this stage. Certain promising drugs may be developing, though we have yet to see the results.
If we wait, such new drugs may join to our arsenal in the fight against cancer. However, we cannot be too optimistic; to realize the Hippo-targeted therapy, there are several barriers to clear. We need to identify good druggable targets. To obtain approval for drugs, we are required to clearly demonstrate their superiority over conventional drugs. It is also a good strategy to repurpose the already approved drugs as the Hippo-targeted drugs. To avoid severe side effects, we must understand precisely how the activation of the Hippo pathway affects cancer pathophysiology.
This Special Issue will highlight a part of the efforts of researchers towards the realization of Hippo-targeted therapy and provide a forum for brainstorming.
Prof. Yutaka Hata
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.